Elecsys® GDF-15 assay discovered as a Companion Diagnostic (CDx) for the treatment of cancer. It helps in finding patients suitable for innovative treatment addressing unintentional weight loss in cancer patients.
Elecsys GDF-15 a quantitative serologic which uses the format of sandwich test for the detection of GDF-15 in human serum. This helps in identifying solid tumours for treatment with PF-06946860 in patients 18 years of age and older.
Cachexia results in metabolic disorder which arises with several chronic diseases such as cancer, heart failure, Chronic Obstructive Pulmonary Disease (COPD), and Chronic Kidney Disease (CKD). It is a major complication of cancer affecting more than half of cancer patients worldwide.
GDF-15 is associated with cachexia in cancer patients, leading to successful cachexia treatment with better outcomes globally.
U.S. Food and Drug Administration (FDA) grants Breakthrough Device Designation to Elecsys® GDF-15 assay as a Companion Diagnostic (CDx) in cancer treatment.
